Management of incidental STIC lesions with and without BRCA mutations: a survey of current clinical practice in Austria, Germany, and Switzerland

• by Natalia Anna Kaufmann, Peter Oppelt, Christoph Grimm, Julia Lastinger, Teresa Eichinger, Philip Trautner, Anja Hartl, Stefan Raidl, Dariga Ramazanova, Caroline Ines Preuss

• April 20, 2026

Ultrasonography-Guided Core Needle Biopsy in the Diagnostic Pathway of Pelvic Tumors

• by Stefan Timmerman, Cristina Taliento, Jolien Haesen, Susan Dababou, Federica Pozzati, Lorena Quagliozzi, Francesca Moro, Floriana Mascilini, Antonia Testa, Filip Frühauf, Roman Kocian, Daniela Fischerova, Elisabeth Epstein, Robert Fruscio, Ashleigh Ledger, Thierry Van den Bosch, Wouter Froyman

• August 14, 2026

Medical debt linked to higher late-stage cancer rates

Lung cancer showed the strongest absolute association, while prostate and breast cancer findings diverged from the broader pattern.

• by Andrea Surnit

• October 9, 2026

• 4 min

FDA approves combo for ESR1-mutated breast cancer

In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.

• by Kathryn Wighton

• September 21, 2026

• 2 min